Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTC4S | Q16873 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 8/20 | 0.51 |
| ▸ | NPC1 | O15118 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282071 | 0.84 | LTC4S (0.51) | LTC4SRAB9ANPC1SMN1; SMN2CASP3 | |
| SCHEMBL1281511 | 0.80 | RAB9A (0.56) | LTC4SRAB9ANPC1SMN1; SMN2CASP3 | |
| SCHEMBL1282218 | 0.79 | S1PR1 (0.56) | — | |
| SCHEMBL1560535 | 0.78 | RAB9A (0.44) | RAB9ANPC1SMN1; SMN2MAPTPKM | |
| SCHEMBL309572 | 0.76 | RAB9A (0.55) | RAB9ANPC1CASP3HDAC1HDAC3 | |
| SCHEMBL6588596 | 0.73 | HDAC1 (0.77) | RAB9ANPC1SMN1; SMN2HDAC1ABCB1 | |
| SCHEMBL30369924 | 0.73 | HDAC1 (0.77) | RAB9ANPC1SMN1; SMN2HDAC1ABCB1 | |
| SCHEMBL5696419 | 0.73 | DHODH (0.69) | LTC4SRAB9ANPC1SMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL29693057 | 0.72 | HDAC1 (0.74) | RAB9ANPC1SMN1; SMN2HDAC1ABCB1 | |
| SCHEMBL30739633 | 0.71 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364976-B1 | S1P receptor modulating compounds and use thereof | EPIX PHARM INC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20120088749-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088749-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088749-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8080542-B2 | S1P receptor modulating compounds and use thereof | AMGEN, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080542-B2 | S1P receptor modulating compounds and use thereof | AMGEN, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080542-B2 | S1P receptor modulating compounds and use thereof | AMGEN, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| EP-2188252-B1 | 1-(4-(4-BENZYLBENZAMIDO)-BENZYL)AZETIDINE-3-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS S1P RECEPTOR MODULATORS FOR THE TREATMENT OF IMMUNE DISORDERS | AMGEN INC (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7919519-B2 | 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease | EPIX PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-2188252-A2 | 1-(4-(4-BENZYLBENZAMIDO)-BENZYL)AZETIDINE-3-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS S1P RECEPTOR MODULATORS FOR THE TREATMENT OF IMMUNE DISORDERS | Amgen Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090082331-A1 | S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082331-A1 | S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082331-A1 | S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2009038759-A2 | 1-(4-(BENZYLBENZAMID0) -BENZYL) AZETIDINE-3-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS SLP RECEPTOR MODULATORS FOR THE TREATMENT OF IMMUNE DISORDERS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038759-A2 | 1-(4-(BENZYLBENZAMID0) -BENZYL) AZETIDINE-3-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS SLP RECEPTOR MODULATORS FOR THE TREATMENT OF IMMUNE DISORDERS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | EPIX DELAWARE, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2007109334-A2 | SIP RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | EPIX DELAWARE, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027036-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | LTC4S 43/4885RAB9A 1945/4885NPC1 2641/4885 |
| US-20110212940-A1 | S1P Receptor Modulating Compounds and Use Thereof | S1PR1, S1PR5, S1PR2 | LTC4S 43/4885RAB9A 1945/4885NPC1 2641/4885 |
| US-20090082331-A1 | S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF | S1PR1, S1PR4, S1PR2 | LTC4S 54/4885RAB9A 2151/4885NPC1 2707/4885 |
| US-20120088749-A1 | S1P Receptor Modulating Compounds and Use Thereof | S1PR1, S1PR4, S1PR2 | LTC4S 37/4885RAB9A 2097/4885NPC1 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.